Announced Fri, 8 Aug · 11:58 IST

Standalone and Consolidated Unaudited Financial Results for Q1FY26

Revenue DeclinePat NegativeResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Makers Laboratories Ltd reported Q1FY26 results with standalone revenue growing ~11.7% year-on-year to Rs. 1,372.68 Lacs, but the standalone business slipped into a wider loss of Rs. 121.89 Lacs versus a loss of Rs. 27.20 Lacs in Q1FY25. On a consolidated basis, revenue declined about 15.5% YoY to Rs. 2,959.17 Lacs, but consolidated profit after tax swung sharply to Rs. 1,090.75 Lacs from a loss of Rs. 341.68 Lacs a year earlier. The consolidated turnaround was largely helped by the subsidiary Resonance Specialties Ltd (45.48% holding), which contributed Rs. 163.16 Lacs in net profit on revenues of Rs. 2,150.13 Lacs. The company has two reportable segments — Pharmaceuticals and Chemical Manufacturing — on a consolidated basis. The statutory auditor N V C & Associates LLP (formerly Natvarlal Vepari & Co, converted into LLP in March 2025) issued a clean, unqualified limited review report with no qualifications or emphasis of matter.

Likely market impact

Mixed picture for shareholders: the standalone pharma business is loss-making and the gap is widening, while the consolidated numbers improved mainly because of the subsidiary's contribution. Investors should watch whether the standalone core business returns to profitability in coming quarters and whether subsidiary earnings remain stable.